Apr 26, 2013
Freedom will become a wholly owned subsidiary of the Fagron Group, a global market leader in pharmaceutical compounding.
TULSA, Oklahoma – April 25, 2013 – Freedom Pharmaceuticals, Inc. announced today that they have been acquired by Arseus, the holding company for Fagron, a global leader in pharmaceutical
compounding. Freedom will immediately become a wholly owned subsidiary of Fagron.
Freedom Pharmaceuticals, a privately held company located in Tulsa, Okla., specializes in the custom wholesale distribution of fine compounding chemicals – active pharmaceutical ingredients (APIs) and excipients – to independent compounding pharmacies throughout the United States.
“I am looking forward to combining forces with the Fagron Group. Fagron’s global and rapidly expanding network offers great potential to roll out successful and unique products and concepts internationally,” Jacob (Jake) Jackson, President of Freedom Pharmaceuticals, said. “Our clients will benefit from an excellent range of more than 1,500 high quality products and services, and our employees will enjoy opportunities for further development in an international environment. Further, I look forward to the opportunity of serving as President of Fagron North America and contributing to the future growth and expansion of both Freedom Pharmaceuticals and the Fagron Group.”
Jackson will continue to serve as President and CEO of Freedom Pharmaceuticals and will assume the position of President of Fagron North America in January 2014.
Connect with thousands of pharmacy professionals throughout every practice setting.